Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18122 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Donghee Kim and 3 co-authors. Institution: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA. Major MEDLINE topics: COVID-19, Financial Stress, Liver Diseases, Drug Monitoring. Cited 9 times so far (Crossref); 15 references.
Abstract (original language)
Background
Economic hardship associated with chronic liver disease (CLD) may delay timely access to healthcare.
Aim
To estimate the national burden of financial hardship across the spectrum of CLD in the United States (US) during the coronavirus disease 2019 (COVID‐19) pandemic.
Methods
A cross‐sectional analysis was performed using the 2020–2021 US National Health Interview Survey database. The questionnaire defined financial hardship from medical bills and cost‐related nonadherence to medications in patients with CLD. We used weighted survey analysis to obtain the national estimates.
Results
While 6.9% (95% confidence interval [CI]: 6.7%–7.2%) out of 60,689 US adults (weighted sample: 251 million) reported financial hardship and inability to pay medical bills; 10.6% (95% CI: 8.3%–13.4%), 18.2% (95% CI: 14.5%–22.6%), 22.6% (95% CI: 11.0%–41.0%) with hepatitis, CLD/cirrhosis, and liver cancer experienced an inability to pay their medical bills due to financial hardship, respectively. 19.8% (95% CI: 15.9%–24.5%) and 23.3% (95% CI: 12.5%–39.3%) with CLD/cirrhosis and liver cancer, respectively experienced cost‐related nonadherence to medications, compared to a tenth of US adults (10.7%, 95% CI: 10.3%–11.2%). CLD/cirrhosis demonstrated an independent association with financial hardship from medical bills and cost‐related nonadherence to medications. Overall, these disparities were more pronounced in individuals aged
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, Arizona, USA.
ORCID profiles: Donghee Kim, Richie Manikat, Karn Wijarnpreecha, Aijaz Ahmed
Cite
APA
Kim, D., Manikat, R., Wijarnpreecha, K., & Ahmed, A. (2024). Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18122
Vancouver
Kim D, Manikat R, Wijarnpreecha K, Ahmed A. Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18122
BibTeX
@article{Kim2024,
author = {Kim, Donghee and Manikat, Richie and Wijarnpreecha, Karn and Ahmed, Aijaz},
title = {Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18122}
}
EUVIMED